Hua Medicine

Executive Summary

Hua Medicine is a commercial-stage biopharmaceutical company based in Shanghai, China, dedicated to developing and commercializing innovative therapies for metabolic diseases, with a primary focus on diabetes. Its lead asset, dorzagliatin (HMS5552), is a first-in-class glucokinase activator (GKA) that received marketing approval in China in 2022 as a monotherapy for type 2 diabetes and subsequently for combination with metformin. Dorzagliatin works by restoring glucose homeostasis through a novel mechanism, addressing the root cause of the disease. With China's diabetes epidemic affecting over 140 million patients, the drug has significant market potential. The company has built a commercial infrastructure in China and is pursuing additional indications and combination trials to broaden its label. Despite competition from other diabetes therapies, dorzagliatin's unique mechanism and favorable safety profile position it as a differentiated option. Hua Medicine continues to explore strategic partnerships for global markets, seeking to expand beyond China.

Upcoming Catalysts (preview)

• Q2 2026Phase 3 trial results for dorzagliatin combination with DPP-4 inhibitors80% success
• H2 2025Strategic partnership for ex-China commercialization60% success
• Q1 2026Potential inclusion in national reimbursement drug list (NRDL) expansion70% success